Diabetes, Insulin Resistance and Dyslipidemia| Volume 13, ISSUE 3, e5-e6, May 2019

A Randomized Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidemia on Background Statin: Primary Results of the BERSON Clinical Trial

      Advisory board and steering committee member for and has received research grants and speaker fees from Amgen Inc.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect